Form 8-K
8-K — Entera Bio Ltd.
Accession: 0001178913-26-004178
Filed: 2026-08-18
Period: 2026-08-18
CIK: 0001638097
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Regulation FD Disclosure
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — zk2635983.htm (Primary)
EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)
GRAPHIC (image_002.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: zk2635983.htm · Sequence: 1
false
0001638097
00-0000000
0001638097
2026-08-18
2026-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 18, 2026
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Israel
001-38556
Not Applicable
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification)
Kiryat Hadassah, Minrav Building – Fifth
Floor, Jerusalem, Israel 9112002
(Address of principal executive offices) (Zip Code)
+972-2-532-7151
(Registrant’s Telephone Number, Including
Area Code)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
ENTX
Nasdaq Capital Market
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On August 18, 2026, Entera Bio Ltd., a company
organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”),
issued a press release announcing the appointment of Dr. Riccardo Paolo Camisasca as the Company’s Chief Medical Officer as described
below in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated by reference in this Item 7.01.
The information contained in Item 7.01 of this
Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act
of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 8.01 Other Events.
On August 18, 2026, the Company appointed Dr.
Riccardo Paolo Camisasca as the Company’s Chief Medical Officer, effective immediately.
Dr. Camisasca is a physician with more than 30
years of experience spanning clinical development, medical affairs, regulatory strategy and R&D leadership. Most recently, he served
as Global Head of Research & Development at Sumitomo Pharma Switzerland, where he led the integration of the R&D organizations
across Urovant, Enzyvant, Altavant, and Myovant. In that role he was responsible for clinical development, global trial execution and
strategic alliance management across all four portfolios. Previously, he led the clinical development and medical affairs divisions at
Bial. He has also held a series of positions of increasing responsibility at Syneos Health, Takeda and Novartis. Earlier in his career,
Dr. Camisasca spent approximately 10 years as a physician and researcher at San Raffaele Hospital in Milan, including work in endocrinology
and metabolic disease. He earned his Medical Degree with honors and specialized in Clinical Pharmacology at the University of Milan.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No
Description
99.1
Press Release dated August 18, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTERA BIO LTD.
Date: August 18, 2026
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: exhibit_99-1.htm · Sequence: 2
Exhibit 99.1
Entera Appoints Global Pharmaceutical
Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Dr. Camisasca joins Entera with 30 years of global pharmaceutical
research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis
Appointment further strengthens Entera’s clinical execution
team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation
TEL AVIV, Israel, August 18, 2026 -- Entera Bio
Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced
the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer. Dr. Camisasca is a physician, clinical pharmacologist and
global pharmaceutical executive with more than 30 years of experience spanning clinical development, medical affairs, regulatory strategy
and R&D leadership. Most recently, he served as Global Head of Research & Development at Sumitomo Pharma Switzerland.
“I am thrilled to welcome Riccardo to the
Entera team. Riccardo’s appointment represents a further strengthening of our clinical leadership as we transition into late-stage
clinical execution and advance our broader oral peptide pipeline,” said Miranda Toledano, Chief Executive Officer of Entera. “Riccardo
brings the rare combination of successfully developing drugs across disparate global R&D organizations. He is thoughtful, rigorous
and most importantly, immediately synergizes with our existing clinical operations and development team.”
“Entera
has reached an important inflection point, with a scarce oral peptide platform, and a potentially transformational asset in EB613
as the first oral anabolic treatment for osteoporosis,” said Dr. Camisasca.
“I have spent my career advancing medicines through increasingly complex stages of clinical development, and I believe Entera has
built a strong foundation for its next phase of growth. I look forward to working with Miranda and the team to execute the EB613 Phase
3 program with the discipline required for registrational development and to help translate the potential of Entera’s broader pipeline
into meaningful therapies for patients.”
Dr. Camisasca is a physician with more than 30
years of experience spanning clinical development, medical affairs, regulatory strategy and R&D leadership. Most recently, he served
as Global Head of Research & Development at Sumitomo Pharma Switzerland, where he led the integration of the R&D organizations
across Urovant, Enzyvant, Altavant, and Myovant. In that role he was responsible for clinical development, global trial execution and
strategic alliance management across all four portfolios. Previously, he led the clinical development and medical affairs divisions at
Bial, where he managed a team of approximately 90 people. He has also held a series of positions of increasing responsibility at Syneos
Health, Takeda and Novartis. Over his career, Dr. Camisasca has worked across the development continuum, from clinical pharmacology and
early development through Phase 3 studies and commercialization, with therapeutic experience spanning cardiovascular and metabolic diseases,
obesity, rare diseases, neuroscience, urology and women’s health. Earlier in his career, Dr. Camisasca spent approximately 10 years
as a physician and researcher at San Raffaele Hospital in Milan, including work in endocrinology and metabolic disease. He earned his
Medical Degree with honors and specialized in Clinical Pharmacology at the University of Milan.
About EB613
Substantial evidence supports the efficacy of
anabolic therapies over anti-resorptive agents for lowering fracture risk in osteoporosis patients at high risk. However, all available
anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. Entera’s EB613 program
(oral PTH(1-34), teriparatide) is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Entera completed
a Phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns
in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose-proportional increases in biochemical markers
of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck BMD. The effects
of EB613 on trabecular and cortical bone using 3D-DXA showed increases with EB613 compared to placebo on a variety of indices, including
integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest
that bone strengthening and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with that of published
subcutaneous teriparatide at the 6-month time point.
About Entera
Entera is a clinical stage company focused on
developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential
to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline
of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed
as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study
of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first
oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin,
a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as
an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration
with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.
Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of
historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities,
collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited
to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,”
“design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,”
“predict,” “project,” “target,” “likely,” “should,” “will,” and
“would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking
statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking
statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance
or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s
forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the
FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned
preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources,
either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera
may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product
candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to
conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s
operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products
on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions
and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity;
Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply
with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company
in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors
that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on
Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes
stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking
statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release,
and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by law.
Company Contact:
IR@enterabio.com
GRAPHIC
GRAPHIC
Filename: image_002.jpg · Sequence: 6
Binary file (5495 bytes)
Download image_002.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
Aug. 18, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 18, 2026
Entity File Number
001-38556
Entity Registrant Name
Entera Bio Ltd.
Entity Central Index Key
0001638097
Entity Tax Identification Number
00-0000000
Entity Incorporation, State or Country Code
L3
Entity Address, Address Line One
Kiryat Hadassah, Minrav Building
Entity Address, Address Line Two
Fifth
Floor
Entity Address, City or Town
Jerusalem
Entity Address, Country
IL
Entity Address, Postal Zip Code
9112002
City Area Code
972
Local Phone Number
2-532-7151
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Ordinary Shares, par value of NIS 0.0000769
Trading Symbol
ENTX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration